Literature DB >> 27201846

Validating A Model To Predict Disease Progression Outcomes In Patients With COPD.

N A Risebrough1, A Briggs2, T M Baker3, A Exuzides4, C Colby4, M Rutten van-Molken5, S Gonzalez McQuire6, D Lomas7, H Muellerova6, R Tal-Singer8, A Ismaila9.   

Abstract

Entities:  

Year:  2014        PMID： 27201846     DOI： 10.1016/j.jval.2014.08.1852

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  6 in total

1.  Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.

Authors:  Afisi S Ismaila; Nancy Risebrough; Melanie Schroeder; Dhvani Shah; Alan Martin; Emma C Goodall; Kerigo Ndirangu; Gerard Criner; Mark Dransfield; David Mg Halpin; MeiLan K Han; David A Lomas
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-11-29

2.  Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.

Authors:  Melanie Schroeder; Nicole Benjamin; Laura Atienza; Chandroday Biswas; Alan Martin; John D Whalen; José Luis Izquierdo Alonso; Juan Antonio Riesco Miranda; Juan José Soler-Cataluña; Alicia Huerta; Afisi S Ismaila
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-10

3.  Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.

Authors:  Soham Shukla; Dhvani Shah; Alan Martin; Nancy A Risebrough; Robyn Kendall; Claus F Vogelmeier; Isabelle Boucot; Lee Tombs; Leif Bjermer; Paul W Jones; Edward Kerwin; Chris Compton; François Maltais; David A Lipson; Afisi S Ismaila
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-11-13

4.  Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

Authors:  M T Driessen; J Whalen; B Seewoodharry Buguth; L A Vallejo-Aparicio; I P Naya; Y Asukai; B Alcázar-Navarrete; M Miravitlles; F García-Río; N A Risebrough
Journal:  Respir Res       Date:  2018-11-20

Review 5.  Personalized medicine for patients with COPD: where are we?

Authors:  Frits Me Franssen; Peter Alter; Nadav Bar; Birke J Benedikter; Stella Iurato; Dieter Maier; Michael Maxheim; Fabienne K Roessler; Martijn A Spruit; Claus F Vogelmeier; Emiel Fm Wouters; Bernd Schmeck
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-07-09

6.  Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective.

Authors:  Dhvani Shah; Maurice Driessen; Nancy Risebrough; Timothy Baker; Ian Naya; Andrew Briggs; Afisi S Ismaila
Journal:  Cost Eff Resour Alloc       Date:  2018-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.